News for Castle Biosciences Inc Stock (CSTL)

Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?

Zacks Investment Research • 06/13/24

Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance

Business Wire • 05/30/24

New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

Business Wire • 05/29/24

Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?

Zacks Investment Research • 05/23/24

What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'

Zacks Investment Research • 05/23/24

Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

Business Wire • 05/15/24

Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024

Business Wire • 05/14/24

Castle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”

Business Wire • 05/10/24

Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result

Business Wire • 05/08/24

Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know

Zacks Investment Research • 05/07/24

Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable

Zacks Investment Research • 05/06/24

Castle Biosciences, Inc. (CSTL) Q1 2024 Earnings Call Transcript

Seeking Alpha • 05/04/24

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

Business Wire • 05/03/24

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research • 05/02/24

Castle Biosciences Reports First Quarter 2024 Results

Business Wire • 05/02/24

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

Business Wire • 04/30/24

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

Business Wire • 04/11/24

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Business Wire • 04/10/24

Castle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

Business Wire • 04/10/24

Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

Business Wire • 04/04/24

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Business Wire • 04/02/24

Castle Biosciences Announces Updates to its Board of Directors

Business Wire • 03/27/24

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

Business Wire • 03/25/24

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Business Wire • 03/22/24

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

Business Wire • 03/19/24